Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Celebrex May Ward Off Skin Cancers

December 1, 2010 7:23 am | News | Comments

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.


Reduced Enzyme Activity Heralds Alzheimer's Onset

December 1, 2010 7:21 am | News | Comments

A scientific report has found evidence of reduced activity of an energy-generating enzyme in deceased young adult brain donors who carry a common genetic risk factor for Alzheimer's disease.


Mutated HIV Lacks Immune Killing Power

December 1, 2010 7:17 am | News | Comments

Mayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves despite a lack of response to standard anti-retroviral treatment. In these cases, researchers say, the virus has lost its ability to kill immune cells.


Antimicrobials A Common Cause of Liver Injury

December 1, 2010 7:15 am | News | Comments

New research shows that anti-microbial medications are a common cause of drug-induced liver injury leading to acute liver failure, with women and minorities disproportionately affected.


FDA Approves Octapharma's IND

December 1, 2010 7:08 am | News | Comments

The U.S. Food and Drug Administration has approved Octapharma USA’s investigational new drug application for octaplex as a fast track product for reversing anticoagulation therapy in patients needing urgent Surgery or invasive procedures.


BioClinica Partners with Kaizen Clinical Services

December 1, 2010 7:02 am | News | Comments

BioClinica, Inc., a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncology-focused contract research organization.


NCCN Snags $2.1M Grant from Pfizer

December 1, 2010 6:59 am | News | Comments

The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.


Scientists Home In on Chemicals Needed to Reprogram Cells

December 1, 2010 6:54 am | News | Comments

Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells.


Janssen And GE Healthcare Working on Biomarkers

December 1, 2010 4:53 am | News | Comments

Janssen Pharmaceutica N.V., announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer's disease prior to the onset of clinical symptoms.


Protein Solubility Kit

November 30, 2010 7:33 am | Product Releases | Comments

Dilyx Biotechnologies’ OptiSol Protein Solubility Screening kit addresses a leading cause of inadvertent protein sample loss: protein aggregation. The kit combines an array of 96 test solutions having different pH, salt, and additives with array-based filtration technology.


PEG Resins for Solid Phase Peptide Synthesis

November 30, 2010 7:30 am | Product Releases | Comments

Biotage has added ChemMatrix resins to its offering of peptide synthesis and purification products. ChemMatrix is a 100% PEG resin from Matrix Innovation that offers advantages over traditional PS and PEG based resins for solid phase peptide synthesis.


Genstruct Changes Name to Selventa

November 30, 2010 7:27 am | News | Comments

Selventa, which evolved from Genstruct, Inc. announced that it has changed its name and launched a re-branded Web site as part of an initiative to provide innovative solutions for its client partners.


Collaboration Focuses on CNS Target Drug Discovery

November 30, 2010 7:25 am | News | Comments

Cisbio Bioassays announced the launch of the GluSense research and development program in partnership with the Functional Genomics Institute. The project, financed by France’s National Research Agency, will focus on the development of CNS drug discovery research tools.


Sanofi Pasteur Starts a Phase 2 Vaccine Trial

November 30, 2010 7:19 am | News | Comments

Sanofi Pasteur has started a Phase 2 clinical study of a vaccine for primary prevention of Clostridium difficile infection. The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals.


Trial Evaluates IMGN901 for Small-Cell Lung Cancer

November 30, 2010 7:14 am | News | Comments

ImmunoGen, Inc. announced the initiation of a randomized Phase 1/2 clinical trial to evaluate its proprietary product candidate, IMGN901, for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.